New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
09:11 EDTA, ABTAgilent unit says white paper supports superiority of HER2 IQFISH pharmDx kit
Dako, an Agilent Technologies (A) company, announced positive findings in a white paper by ProPath Services, an independent anatomic pathology laboratory, comparing Dako's HER2 IQFISH pharmDx kit with Abbott's (ABT) PathVysion HER-2 DNA Probe kit. "The authors found that HER2 IQFISH pharmDxTM provided better overall quality than the PathVysion kit, defined by better signal-to-background ratio enabling more accurate determination of copy numbers. The study also concluded that the Dako kit saved 30-60 minutes of hands-on time per slide, due to less hands-on time required by lab staff, and reduced time required by the pathologist for reading and scoring," Dako said.
News For A;ABT From The Last 14 Days
Check below for free stories on A;ABT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
18:29 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:01 EDTAAgilent board approves separation of Keysight, declares special dividend
Subscribe for More Information
16:57 EDTAAgilent creates new group for services, consumables
Subscribe for More Information
16:55 EDTAAgilent announces Mike McMullen to succeed Bill Sullivan as CEO in March 2015
Subscribe for More Information
September 16, 2014
11:51 EDTABTOECD looks to close tax loopholes with new proposals
Subscribe for More Information
September 15, 2014
09:32 EDTABTAbbott initiates ABSORB IV trial
Abbott announced the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold is more cost-effective and offers a higher quality of life than a permanent, metallic drug eluting stent. Unlike a metallic stent, Absorb completely dissolves over time after doing its job. ABSORB IV is designed to enroll approximately 3K people with coronary artery disease, mostly in the U.S. The ABSORB IV trial is designed to confirm these novel findings that treatment with the Absorb device can help provide people with heart disease a higher quality of life after a heart stent procedure. The data from the ABSORB IV trial will be combined with the data from the ABSORB III trial to create a population of more than 5K people studied in the U.S. This data set, which is the largest of its kind for bioresorbable heart devices, provides an opportunity to evaluate the performance of Absorb compared to the current standard of a metallic drug eluting stent across a number of measures, including the broader health economic impact of this innovative therapy.
07:45 EDTABTCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
September 14, 2014
13:30 EDTABTAbbott announces positive one-year clinical results from ABSORB II
Subscribe for More Information
September 12, 2014
14:03 EDTAKeysight enters into manufacturing test license agreement with Broadcom
Subscribe for More Information
September 11, 2014
13:41 EDTABTAbbott announces new $3B share repurchase program
Subscribe for More Information
September 9, 2014
06:42 EDTABTLew expects to make decision on combating inversion deals soon, NY Times reports
Subscribe for More Information
September 8, 2014
10:06 EDTAOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AIG (AIG) initiated with a Buy at Citigroup... Agilent (A) initiated with an Equal Weight at Morgan Stanley... Altisource Residential (RESI) initiated with a Neutral at JPMorgan... AngloGold (AU) initiated with an Overweight at JPMorgan... Arista Networks (ANET) initiated with an Outperform at FBN Securities... C1 Financial (BNK) initiated with a Buy at Wunderlich... Cherokee (CHKE) initiated with a Buy at Roth Capital... ContraFect (CFRXU) initiated with a Buy at Maxim... DRDGOLD (DRD) initiated with an Underweight at JPMorgan... Enable Midstream (ENBL) initiated with an Equal Weight at Morgan Stanley... Enservco (ENSV) initiated with an Outperform at Northland... GoPro (GPRO) initiated with an Outperform at FBN Securities... Gold Fields (GFI) initiated with an Overweight at JPMorgan... Gulfport Energy (GPOR) initiated with an Equal Weight at Morgan Stanley... Harmony Gold (HMY) initiated with a Neutral at JPMorgan... Illumina (ILMN) initiated with an Equal Weight at Morgan Stanley... LINN Energy (LINE) reinstated with an Outperform at Credit Suisse... LinnCo (LNCO) reinstated with an Outperform at Credit Suisse... Randgold (GOLD) initiated with a Neutral at JPMorgan... Rentrak (RENT) initiated with a Buy at Needham... Rice Energy (RICE) initiated with an Accumulate at KLR Group... SanDisk (SNDK) initiated with an Outperform at FBN Securities... Seadrill (SDRL) initiated with a Sell at Canaccord... Tesla (TSLA) initiated with an Outperform at FBN Securities... Thermo Fisher (TMO) initiated with an Overweight at Morgan Stanley... Waters (WAT) initiated with an Underweight at Morgan Stanley... Whiting Petroleum (WLL) initiated with an Equal Weight at Morgan Stanley.
07:35 EDTAAgilent initiated with an Equal Weight at Morgan Stanley
Subscribe for More Information
September 5, 2014
05:46 EDTABTDexCom competition closer after Abbott approval, says Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use